Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company, announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, generating $50 million in gross proceeds. The company plans to use the funds to commercialize Symvess®, file a Biologics License Application supplement for hemodialysis indication, and develop pipeline candidates. The offering is expected to close on June 12, 2026.